Normalized Rabbit Antibody Frameworks for Diagnostic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing diagnostic assays face challenges in standardizing antibody properties such as thermal stability, long-term stability, and conjugation ratios due to the uniqueness of rabbit monoclonal antibodies, which affects reproducibility and manufacturing.
Innovation Solution
Designing and manufacturing normalized rabbit antibodies by mutating wild-type antibodies to optimize desirable properties like thermal stability and expression without compromising binding affinity, using specific amino acid residues from thermally stable rabbit antibodies as templates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type rabbit monoclonal antibodies are used for diagnostic assays, then binding specificity to target antigens is achieved, but thermal stability and long-term stability are insufficient affecting assay reproducibility
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues in the antibody framework regions (FR1-FR4) of rabbit monoclonal antibodies. Specific substitutions are made at positions such as FR1:40, FR1:41, FR2:38, FR2:39, FR3:56, and FR4:115 to optimize thermal stability and long-term stability while preserving antigen binding capability. This direct modification of molecular parameters resolves the contradiction between maintaining reliability and improving stability.
Solution Approach 2:
The patent creates universal normalized antibody frameworks that can serve multiple diagnostic applications. By establishing standardized framework regions with optimized stability parameters, the same framework structure can be applied across different rabbit monoclonal antibodies for various target antigens, achieving both improved stability and broad applicability in diagnostic assays.
2Manufacturing precision
If rabbit monoclonal antibodies are standardized for manufacturing, then manufacturing precision and reproducibility improve, but the uniqueness of each antibody's framework region must be modified
Solution Approach 1:
The patent applies homogeneity by standardizing the antibody framework regions across different rabbit monoclonal antibodies. Specific amino acid sequences in FR1-FR4 are normalized to create uniform structures that enable consistent manufacturing parameters, conjugation ratios, and batch-to-batch reproducibility. This reduces framework region heterogeneity while preserving the unique CDR regions that determine antigen specificity.
Solution Approach 2:
The patent segments the antibody structure into distinct functional regions: standardized framework regions (FR1-FR4) for manufacturing consistency and unique complementarity determining regions (CDRs) for antigen binding. This segmentation allows independent optimization of manufacturing precision through framework standardization without affecting the specificity-determining CDR sequences.
3Stability of the object's composition
If amino acid residues are mutated to improve thermal stability, then long-term stability increases, but binding affinity to target may be compromised
Solution Approach 1:
The patent applies local quality by making targeted amino acid substitutions only in specific framework region positions (FR1:40, FR1:41, FR2:38, FR2:39, FR3:56, FR4:115) that do not directly contact the antigen. These localized modifications improve thermal and long-term stability while leaving the CDR regions and critical framework residues untouched, thereby preserving binding affinity and specificity to target antigens.
Data Source
AI summary
The invention provides methods of designing and manufacturing universal or normalized sequence templates for rabbit monoclonal antibodies for diagnostic applications. The invention further provides for methods of optimizing desirable antibody properties, such as thermal stability, long-term stability, expression, deamination/oxidation, and/or aggregation. The invention further provides for universal or normalized rabbit monoclonal antibody templates or frameworks and antibodies derived therefrom.